Increased hypothalamic-pituitary-adrenal (HPA) axis activity in aging and AD may be a risk factor for the psychopathology of Alzheimer's disease (AD). This application proposes to continue to define mechanisms underlying increased HPA axis activity in AD. It also proposes to evaluate the ability of an antidepressant drug to reduce HPA axis responsiveness in AD and normal aging and to reduce the depressive signs and symptoms that frequently complicate AD. During the current funding period we have demonstrated in normal aging reduced sensitivity o the HPA axis to feedback inhibition by the endogenous glucocorticoid (GC) cortisol. Preliminary data suggest even further reduced sensitivity to GC feedback inhibition and increased basal HPA axis activity in early onset AD. The following Specific Aims will be pursued in groups of early onset AD, late onset AD, and normal old subjects:
Specific Aim 1 will address the hypothesis that HPA axis sensitivity to GC feedback inhibition is reduced in early onset AD. The adrenocorticotropin (ACTH) response to a 150-minute exogenous cortisol infusion will be measured following removal of endogenous GC feedback by the cortisol synthesis inhibitor metyrapone. In addition, 24 hour urinary free cortisol and morning, afternoon and evening salivary cortisol will be measured to assess integrated HPA axis activity and cortisol diurnal rhythm.
Specific Aim 2 will address the hypotheses that (a) the selective serotonin reuptake inhibitor antidepressant drug sertraline increases HPA axis sensitivity to GC feedback inhibition; and (b) sertraline reduces subsyndromal depressive signs and symptoms in AD. The proposed studies will determine the effects of a twelve-week course of sertraline or placebo on (a) HPA axis activity in all subjects (ACTH response to the metyrapone/cortisol protocol; 24 hour urinary free cortisol; morning, afternoon and evening salivary cortisols) and on (b) the presence and severity of depressive signs and symptoms in AD subjects. The results of the proposed studies will more clearly define mechanisms contributing to increased HPA axis activity in AD. Demonstrating increased HPA axis activity in early onset AD compared to late onset AD will provide supportive evidence that increased HPA axis activity is a risk factor for early expression of AD. The proposed studies also will evaluate the ability of an antidepressant to modify this potential risk factor for the expression of AD and provide a controlled treatment trial of a selective serotonin reuptake inhibitor for depressive signs and symptoms in AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG008419-10
Application #
2899743
Study Section
Mental Disorders of Aging Review Committee (MDA)
Project Start
1989-01-01
Project End
2001-03-31
Budget Start
1999-04-01
Budget End
2001-03-31
Support Year
10
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Washington
Department
Psychiatry
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Pan, Sheng; Zhu, David; Quinn, Joseph F et al. (2007) A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics 7:469-73
Pan, Sheng; Wang, Yan; Quinn, Joseph F et al. (2006) Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach. J Proteome Res 5:2769-79
Li, Ge; Cherrier, Monique M; Tsuang, Debby W et al. (2006) Salivary cortisol and memory function in human aging. Neurobiol Aging 27:1705-14
Peskind, Elaine R; Li, Ge; Shofer, Jane et al. (2006) Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 63:936-9
Vuletic, Simona; Peskind, Elaine R; Marcovina, Santica M et al. (2005) Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro. J Neurosci Res 80:406-13
Peskind, Elaine R; Riekse, Robert; Quinn, Joseph F et al. (2005) Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 19:220-5
Clark, Christopher M; Xie, Sharon; Chittams, Jesse et al. (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60:1696-702
Vuletic, Simona; Jin, Lee-Way; Marcovina, Santica M et al. (2003) Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease. J Lipid Res 44:1113-23
Petrie, E C; Peskind, E R; Dobie, D J et al. (2001) Plasma catecholamine and cardiovascular responses to physostigmine in Alzheimer's disease and aging. Psychoneuroendocrinology 26:147-64
Peskind, E R; Griffin, W S; Akama, K T et al. (2001) Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int 39:409-13

Showing the most recent 10 out of 49 publications